BEAT: Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy

Sponsor
Keimyung University Dongsan Medical Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT03590730
Collaborator
Medtronic (Industry)
122
12
72
10.2
0.1

Study Details

Study Description

Brief Summary

The prevalence of valvular heart disease is on the rise along with the aging society and the generalization of echocardiography. Furthermore, the rheumatic valvular heart disease is much more prevalent in Asia than in Western countries, and the frequency of valve disease is higher in Asia. The effect of an implantable cardioverter defibrillator (ICD) in the primary prevention of sudden cardiac death in ischemic cardiomyopathy is well established and has become a standard of care. However, there is limited research on the effect of ICD implantation for primary prevention in patients with heart failure due to valvular heart disease. In a small study, the incidence of fatal cardiac arrhythmia was lower in patients with valvular cardiomyopathy (5%) who received ICD implantation for primary prevention than in those with ischemic cardiomyopathy. But there is also a report that the appropriate ICD treatment is not different from that of ischemic heart disease in valvular heart disease patients. Therefore, it is necessary to study the primary prevention effect of ICD on valvular cardiomyopathy in a larger number of patients. The purpose of this study was to investigate the effect of ICD on the prevention of sudden cardiac death in patients with heart failure due to valvular heart disease through prospective, multicenter, and observational studies.

Condition or Disease Intervention/Treatment Phase
  • Device: ICD implantation

Study Design

Study Type:
Observational
Anticipated Enrollment :
122 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Benefits of ICD for the Primary Prevention in Patients With Valvular Cardiomyopathy
Actual Study Start Date :
Nov 15, 2017
Anticipated Primary Completion Date :
Nov 15, 2023
Anticipated Study Completion Date :
Nov 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Valvular heart disease

Patients with left ventricular dysfunction due to valvular heart disease who received ICD implantation for primary prevention of sudden cardiac death.

Device: ICD implantation
ICD will be implanted according to current guidelines recommendations.

Outcome Measures

Primary Outcome Measures

  1. Incidence of Appropriate ICD therapy [Two year after study enrollment]

    ICD therapy that effectively terminate life-threatening arrhythmia: anti-tachycardia pacing, shock therapy

Secondary Outcome Measures

  1. Mortality [Two year after study enrollment]

    mortality was recorded and it will be classified into cardiogenic/non-cardiogenic death. Especially, arrhythmic death was recorded separately.

  2. Incidence of inappropriate ICD therapy [Two year after study enrollment]

    Inappropriately delivered ICD therapy (eg. ICD therapy delivered during sinus tachycardia)

  3. Type of ventricular arrhythmia [Two year after study enrollment]

    Analyze the type of ventricular arrhythmia

Eligibility Criteria

Criteria

Ages Eligible for Study:
19 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients who meet one of the following criteria:

  • Patients who have undergone surgery for aortic valve or mitral valve disease for more than 12 months

  • Patients with severe aortic valve or mitral valve disease

  • Patients with left ventricular ejection fraction ≤ 35% by echocardiography or other imaging methods

  • US, European practice guidelines class I indication for ICD implantation

  • Patients without evidence of ischemic heart disease (who meet one of the following criteria):

  • Stress test negative

  • Significant stenosis was not observed in coronary artery images:

epicardial coronary stenosis <70%, left main stenosis <50%

  • History of heart failure symptoms

  • Patients who have received medication for more than 3 months according to the heart failure treatment guideline recommendation

Exclusion Criteria:
  • Patients with left ventricular dysfunction without valvular heart disease

  • Patients who require cardiac pacing therapy due to bradycardia

  • Heart transplant scheduled

  • Life expectancy is less than one year

Contacts and Locations

Locations

Site City State Country Postal Code
1 Pusan National University Yangsan Hospital Yangsan Gyeongsangnam-do Korea, Republic of 50612
2 Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital Daegu Korea, Republic of 41944
3 Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital Daegu Korea, Republic of 42415
4 Chonnam National University Hospital Gwangju Korea, Republic of 61469
5 Mediplex Sejong Hospital Incheon Korea, Republic of 21080
6 Seoul National University Bundang Hospital Seongnam Korea, Republic of 13620
7 Korea University Anam Hospital Seoul Korea, Republic of 02841
8 Seoul National University Hospital Seoul Korea, Republic of 03080
9 Severance Cardiovascular Hospital Seoul Korea, Republic of 03722
10 Seoul Asan Medical Center Seoul Korea, Republic of 05505
11 Seoul Samsung Medical Center Seoul Korea, Republic of 06351
12 Seoul St. Mary's Hospital Seoul Korea, Republic of 06591

Sponsors and Collaborators

  • Keimyung University Dongsan Medical Center
  • Medtronic

Investigators

  • Principal Investigator: Seongwook Han, MD, Ph D, Keimyung University Dongsan Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Keimyung University Dongsan Medical Center
ClinicalTrials.gov Identifier:
NCT03590730
Other Study ID Numbers:
  • 2017-08-027-007
First Posted:
Jul 18, 2018
Last Update Posted:
Mar 15, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 15, 2022